Cooper Companies, Inc.

COO

Nasdaq; healthcare; SIC 3851, Ophthalmic Goods; CIK 0000711404

C

middle fifth of 370 graded peers in healthcare

rank 211 of 370; percentile 56.9; sampling error 2.5 points; lower is stronger



C, the tortoise



Scoreboard


Profitability	C percentile 51.5
Solvency	C percentile 49.7
Growth and financing	C percentile 49.2
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $12.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	12 of 14
Graded from	filings received through Dec 5, 2025 328 days before the rescan; latest periodic filing 10-Q received Sep 9, 2026
Last close	$59.53 2026-10-28; market equity $11.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Dec 5, 2025

The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year. Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women's health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 51.5						
Gross profitability	21.6%	32.3%		62.8	369	2025-10-31
Return on invested capital	4.3%	9.3%		63.0	74	2025-10-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(3.4%)	(6.6%)	69.4	805	2025-10-31
Gross margin stability, five years	0.8 pts	2.8 pts	10.8	242	2025-10-31
Solvency, sleeve percentile 49.7					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	4.99	(0.33)	18.8	751	2025-10-31
Net debt to EBITDA	2.21x	1.82x	56.8	75	2025-10-31
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-10-31; latest annual assets end 2025-10-31					
Current ratio	1.89x	2.94x	73.5	832	2025-10-31
Growth and financing, sleeve percentile 49.2					
Revenue growth, three-year compound	7.3%	10.1%	55.3	413	2025-10-31
Free cash flow growth, three-year compound	(1.3%)	10.9%	74.7	96	2025-10-31
Reinvestment rate	11.0%	37.1%	63.1	104	2025-10-31
Asset growth, three years	2.6%	2.1%	45.8	697	2025-10-31
Net share issuance, one year	(1.8%)	2.5%	7.1	633	2025-12-01

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
206	Regenxbio Inc. (RGNX)	55.6	C	short runway
207	ELI Lilly & Co. (LLY)	55.8	C	
208	Inogen Inc. (INGN)	56.1	C	fortress balance sheet
209	AdaptHealth Corp. (AHCO)	56.4	C	
210	Aquestive Therapeutics, Inc. (AQST)	56.6	C	
211	Cooper Companies, Inc. (COO)	56.9	C	
212	Perspective Therapeutics, Inc. (CATX)	57.2	C	dilution, fortress balance sheet
213	Cryo Cell International Inc. (CCEL)	57.5	C	
214	electroCore, Inc. (ECOR)	57.7	C/D	
215	Rocket Pharmaceuticals, Inc. (RCKT)	58.0	C/D	degenerate inputs
216	Prestige Consumer Healthcare Inc. (PBH)	58.3	C/D	

What the price implies

at the 2026-10-28 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	2.2%	7.7%	47
Distance from 52-week high	(29.5%)	(27.7%)	46
EBIT to enterprise value	5.2%	(1.5%)	81
Free cash flow yield	3.8%	(1.0%)	74
Book value to price	0.74	0.27	79
Sales to price	0.36	0.31	56
Composite equity issuance, five years	(3.3%)	20.5%	22

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	(0.19)	(0.14)	47

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-10-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$154.7M
Operating cash flow, four quarters	$1.0B
Months of runway	not finite
Days since last periodic filing	50 (10-Q received Sep 9, 2026)
Median daily dollar volume, 63 sessions	$173.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2.7B	2025-10-31	2025-12-05	10-K	25-055615
2	assets	us-gaap:Assets	$12.4B	2025-10-31	2025-12-05	10-K	25-055615
3	operating income	us-gaap:OperatingIncomeLoss	$682.9M	2025-10-31	2025-12-05	10-K	25-055615
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$566.5M	2025-10-31	2025-12-05	10-K	25-055615
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$191.6M	2025-10-31	2025-12-05	10-K	25-055615
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$2.5B	2025-10-31	2025-12-05	10-K	25-055615
7	book equity	us-gaap:StockholdersEquity	$8.2B	2025-10-31	2025-12-05	10-K	25-055615
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$110.6M	2025-10-31	2025-12-05	10-K	25-055615
9	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$2.6B	2024-10-31	2025-12-05	10-K	25-055615
10	book equity	us-gaap:StockholdersEquity	$8.1B	2024-10-31	2025-12-05	10-K	25-055615
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$107.6M	2024-10-31	2025-12-05	10-K	25-055615
12	net income	us-gaap:NetIncomeLoss	$374.9M	2025-10-31	2025-12-05	10-K	25-055615
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$796.1M	2025-10-31	2025-12-05	10-K	25-055615
14	assets	us-gaap:Assets	$12.3B	2024-10-31	2025-12-05	10-K	25-055615
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.1B	2025-10-31	2025-12-05	10-K	25-055615
16	gross profit	us-gaap:GrossProfit	$2.6B	2024-10-31	2025-12-05	10-K	25-055615
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.9B	2024-10-31	2025-12-05	10-K	25-055615
18	gross profit	us-gaap:GrossProfit	$2.4B	2023-10-31	2025-12-05	10-K	25-055615
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.6B	2023-10-31	2025-12-05	10-K	25-055615
20	gross profit	us-gaap:GrossProfit	$2.1B	2022-10-31	2024-12-06	10-K	24-000074
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.3B	2022-10-31	2024-12-06	10-K	24-000074
22	gross profit	us-gaap:GrossProfit	$2.0B	2021-10-31	2023-12-08	10-K	23-000072
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.9B	2021-10-31	2023-12-08	10-K	23-000072
24	current assets	us-gaap:AssetsCurrent	$2.1B	2025-10-31	2025-12-05	10-K	25-055615
25	current liabilities	us-gaap:LiabilitiesCurrent	$1.1B	2025-10-31	2025-12-05	10-K	25-055615
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$7.6B	2025-10-31	2025-12-05	10-K	25-055615
27	liabilities	us-gaap:Liabilities	$4.2B	2025-10-31	2025-12-05	10-K	25-055615
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$377.4M	2025-10-31	2025-12-05	10-K	25-055615
29	operating income	us-gaap:OperatingIncomeLoss	$533.1M	2023-10-31	2025-12-05	10-K	25-055615
30	interest expense	us-gaap:InterestExpense	$105.3M	2023-10-31	2023-12-08	10-K	23-000072

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$362.4M	2025-10-31	2025-12-05	10-K	25-055615
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$709.3M	2024-10-31	2025-12-05	10-K	25-055615
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$421.2M	2024-10-31	2025-12-05	10-K	25-055615
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$607.5M	2023-10-31	2025-12-05	10-K	25-055615
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$392.5M	2023-10-31	2025-12-05	10-K	25-055615
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$692.4M	2022-10-31	2024-12-06	10-K	24-000074
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$242.0M	2022-10-31	2024-12-06	10-K	24-000074
38	current assets	us-gaap:AssetsCurrent	$2.0B	2024-10-31	2025-12-05	10-K	25-055615
39	current liabilities	us-gaap:LiabilitiesCurrent	$1.0B	2024-10-31	2025-12-05	10-K	25-055615
40	assets	us-gaap:Assets	$11.7B	2023-10-31	2025-12-05	10-K	25-055615
41	assets	us-gaap:Assets	$11.5B	2022-10-31	2024-12-06	10-K	24-000074
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	195,978,026	2025-12-01	2025-12-05	10-K	25-055615
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	199,582,626	2024-11-29	2024-12-06	10-K	24-000074

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.